Insider Selling: Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells $155,202.48 in Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 3,096 shares of the firm’s stock in a transaction dated Wednesday, March 26th. The stock was sold at an average price of $50.13, for a total transaction of $155,202.48. Following the sale, the director now owns 279,787 shares of the company’s stock, valued at $14,025,722.31. This trade represents a 1.09 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Pro-Dex Stock Down 3.5 %

Shares of NASDAQ PDEX opened at $48.23 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.58 and a quick ratio of 1.44. The stock has a market capitalization of $157.28 million, a PE ratio of 24.00 and a beta of 0.68. Pro-Dex, Inc. has a one year low of $16.84 and a one year high of $59.60. The business’s fifty day moving average price is $40.21 and its 200-day moving average price is $39.99.

Pro-Dex (NASDAQ:PDEX) last issued its earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.23. Pro-Dex had a net margin of 11.06% and a return on equity of 21.68%. On average, equities research analysts anticipate that Pro-Dex, Inc. will post 2 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, StockNews.com downgraded shares of Pro-Dex from a “buy” rating to a “hold” rating in a research report on Wednesday, March 12th.

Hedge Funds Weigh In On Pro-Dex

A number of large investors have recently modified their holdings of the company. FMR LLC lifted its stake in Pro-Dex by 34.9% in the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after purchasing an additional 1,028 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Pro-Dex by 9.1% in the third quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock worth $819,000 after purchasing an additional 2,296 shares during the period. JPMorgan Chase & Co. raised its position in shares of Pro-Dex by 2.2% in the third quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock worth $740,000 after buying an additional 529 shares in the last quarter. Ritholtz Wealth Management bought a new stake in Pro-Dex during the fourth quarter valued at $572,000. Finally, Bank of New York Mellon Corp purchased a new position in Pro-Dex during the fourth quarter worth about $202,000. 15.28% of the stock is currently owned by institutional investors.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.